ENLIVEX THERAPEUTICS LTD ENLV 深 滬
等待開盤 09-10 09:30:00 美东时间
1.02
-0.020
-1.92%
華盛通- 最 高1.05
- 今 開1.04
- 成交量 18.17万股
- 最 低 1.01
- 昨 收 1.04
- 總市值 2433.55万
- 52周最高 2.10
- 市盈率 靜 --
- 換手率 0.76%
- 52周最低 0.8101
- 委 比 -7.47%
- 總股本 2385.83万
- 歷史最高 44.90
- 量 比 0.83
- 振 幅 3.85%
- 歷史最低 0.8101
- 每 手 1
- 風險率 0.20%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Enlivex Secures Israeli Patent For Allocetra In Osteoarthritis Treatment, Extending IP Protection Through 2040
Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of an Israeli patent, numbered 290470, titled, "THERAPEUTIC
09-09 20:03
Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
<p>Enlivex Therapeutics Ltd. has been granted an Israeli patent for using Allocetra™ to treat osteoarthritis, providing protection through at least 2040. The company reported positive Phase IIa data showing 24% knee pain reduction and 26% improvement in knee function with Allocetra™. CEO Oren Hershkovitz expressed confidence in securing similar patents globally. Osteoarthritis affects millions and has no approved treatments to slow joint damage, ...
09-09 12:00
HC Wainwright & Co. Reiterates Buy on Enlivex Therapeutics, Maintains $7 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Enlivex Therapeutics (NASDAQ:ENLV) with a Buy and maintains $7 price target.
09-02 19:16
Enlivex’s Allocetra: A New Hope for Psoriatic Arthritis?
Enlivex Therapeutics (($ENLV)) announced an update on their ongoing clinical st...
08-21 00:16
Enlivex to Present Key Results from Osteoarthritis Trial
An update from Enlivex ( ($ENLV) ) is now available. On August 14, 2025, Enlive...
08-14 20:57
Enlivex To Present 3-Month Topline Data From Phase IIa Stage Of Its Phase I/IIa ENLX-CL-05-001 Trial
Webinar to Review Results from Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Allocetra™ in Patients with Moderate to Severe Knee Osteoarthritis
08-14 20:43
Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar
Enlivex Therapeutics Ltd. will host a webinar on August 18, 2025, at 8:00 AM ET to discuss the 3-month top-line results from the Phase IIa stage of its ENX-CL-05-001 trial, evaluating Allocetra™ in patients with moderate-to-severe knee osteoarthritis. The webinar will feature a detailed analysis of the data from the multi-center, randomized, placebo-controlled study. Osteoarthritis affects millions globally, and knee osteoarthritis is particularl...
08-14 12:30
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data
Enlivex Therapeutics Ltd. announced that all 134 patients in its Phase II trial of Allocetra™ for moderate to severe knee osteoarthritis have completed at least three months of follow-up, with audited topline results expected on August 18, 2025. The Phase I/II trial evaluates safety and efficacy endpoints, including knee pain and function, at three, six, and 12 months. Currently, no approved treatments slow joint damage in osteoarthritis. Enlivex...
07-28 12:30
D. Boral Capital Maintains Buy on Enlivex Therapeutics, Maintains $13 Price Target
D. Boral Capital analyst Jason Kolbert maintains Enlivex Therapeutics (NASDAQ:ENLV) with a Buy and maintains $13 price target.
07-22 20:14
Enlivex Therapeutics To Feature Data From Ongoing Clinical Study Evaluating Proprietary Allocetra Off-The-Shelf Macrophage Reprogramming Cell Therapy, In Patients With Knee Osteoarthritis At EULAR European Congress Of Rheumatology
Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will present a poster at the European Alliance of Associations for
06-10 20:34
